Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Inclusion Criteria: * ECOG 0-2 OR Karnofsky 60-100% * AST and ALT =\< 2.5 times ULN * Bilirubin =\< 1.5 times upper limit of normal (ULN) * Platelet count \>= 100,000/mm3 * Absolute neutrophil count \>= 1,500/mm3 * Creatinine normal OR creatinine clearance ≥ 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Any number and type of prior chemotherapies are allowed including prior use of gemcitabine chemotherapy. A washout phase of at least 2 weeks since use of prior chemotherapy or radiation therapy, 6 weeks if the last regimen included nitrosoureas or mitomycin C, is required. * Patients must have histologically confirmed epithelial malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. * Ability to understand and the willingness to sign a written informed consent document. * Patients must have at least one measurable lesion as per the RECIST Criteria that can be accurately measured in at least one dimension, with minimum lesion size equal to or more than twice the slice thickness of the imaging study used. Exclusion Criteria: * No symptomatic congestive heart failure * No cardiac arrhythmia * No ongoing or active infection * No psychiatric illness or social situation that would preclude study compliance * No history of allergy, significant side effects, or poor tolerance to gemcitabine * No history of allergic reaction attributed to compounds of similar chemical or biological composition to vorinostat (SAHA) * At least 2 weeks since prior radiotherapy * Recovered from prior therapy * No concurrent combination antiretroviral therapy for HIV-positive patients * No other uncontrolled illness * More than 2 weeks since prior valproic acid * No other concurrent investigational drugs * No other concurrent anticancer therapy * Patients with known brain metastases are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.